Following an orphan drug designation earlier in 2021, NUV-422 has been granted a fast track designation for the treatment of high-grade gliomas.
An investigational cyclin-dependent kinase (CDK) 2/4/6 inhibitor, NUV-422, was granted an FDA fast track designation for the treatment of patients with high-grade gliomas, including glioblastoma multiforme, according to a press release by Nuvation Bio Inc.1
NUV-422 is a potent inhibitor of CDK 2, 4, and 6. Preclinical research has shown NUV-422’s ability to penetrate the blood-brain barrier and limit CDK1 inhibition, which can limit the toxicities often observed with other second-generation inhibitors. Previously, the agent received an orphan drug designation from the FDA for the treatment of malignant gliomas.
"We are pleased that NUV-422 received FDA Fast Track designation because it highlights the serious unmet need of patients with brain cancer and the potential of our lead drug candidate NUV-422 to serve as an innovative new treatment option for high-grade gliomas, including glioblastoma multiforme," said David Hung, MD, founder, president, and chief executive officer of Nuvation Bio, in a press release.
The CDK 2/4/6 inhibitor is under investigation in a first-in-human, open-label, phase 1/2 dose-escalation and multiple expansion-cohort study (NCT04541225), which includes adult patients with recurrent or refractory high-grade gliomas and other solid tumors including metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC).2
The study will include 218 patients who will be assessed for the primary end point of the incidence of treatment-emergent adverse events (AEs), serious AEs, and dose-limiting toxicities in phase 1. The phase 2 co-primary end points include objective response rate, duration of response, NUV-422 concentration in plasma, including peak plasma concentration, NUV-422 half-life in plasma, the concentration of NUV-422 in brain tumor tissue, and the effects of NUV-422 on brain tumor cell proliferation ratio pre- and post-treatment.
Patients are eligible to enroll given they have recovered from toxicity caused by prior anti-cancer therapy, have adequate bone marrow and organ function, are appropriate candidates to receive NUV-422 monotherapy, and have a life expectancy of > 3 months. All patients must also have either an ECOG performance score ≤ 2 or a Karnofsky Performance Status score ≥ 60 to be included in phase 1. The phase 2 requirements include histologically confirmed disease, prior radiotherapy, and either a KPS score ≥ 70 or ECOG performance score ≤ 2.
The study is actively recruiting patients with solid tumors in Massachusetts, New York, North Carolina, Texas, and Utah who meet the eligibility requirements.
"Enrollment is ongoing in our expanded Phase 1/2 monotherapy study of NUV-422 for the treatment of adults with recurrent or refractory high-grade gliomas and solid tumors. We look forward to continuing to work closely with the FDA to expedite the development of NUV-422 with data from the Phase 1 portion of the study, which is on track for 2022," said Hung, in the press release.1
References:
1. Nuvation Bio receives FDA fast track designation for NUV-422 for the treatment of high-grade gliomas, including glioblastoma multiforme. News release. Nuvation Bio. December 15, 2021. Accessed December 15, 2021. https://prn.to/3oYyENs
2. Study of NUV-422 in adults with recurrent or refractory high-grade gliomas and solid tumors. Clinicaltrials.gov. Accessed December 15, 2021.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Olaptesed Pegol Wins FDA Fast Track Designation in Brain Cancer
April 3rd 2024The FDA granted a fast track designation to olaptesed pegol with bevacizumab and radiotherapy for patients with newly diagnosed glioblastoma that is resistant to chemotherapy and where measurable tumor remains after surgery.
Read More
TTFields Increases Time to Progression in Patients With Brain Metastases From NSCLC
March 27th 2024Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.
Read More